Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Notes Payables (2016 - 2025)

Historic Notes Payables for Heron Therapeutics (HRTX) over the last 10 years, with Q2 2025 value amounting to $149.8 million.

  • Heron Therapeutics' Notes Payables changed N/A to $149.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $149.8 million, marking a year-over-year change of. This contributed to the annual value of $7.1 million for FY2020, which is 2540.9% up from last year.
  • Per Heron Therapeutics' latest filing, its Notes Payables stood at $149.8 million for Q2 2025.
  • Heron Therapeutics' Notes Payables' 5-year high stood at $149.8 million during Q2 2025, with a 5-year trough of $7.6 million in Q1 2021.